FIG. 1

Heavy Chain

EVQLLESGGGLVKPGQSLKLSCAASGFTFTSYGMHWVRQPPGKGLEWVAVISYDGSYKYYADSVQG
RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSRLRSLLYFEWLSQGYFNPWGAGTTLTVSSAST
KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVV
TVPSSSLGTQTYICNVNHKPSNTKVDKKVEPPKSCDKTHTCPPCPGTELLGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK
EYKCKVSNKALPAPIEKTISKAKGEPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES
NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(SEQ ID NO: 94)

Light Chain

EIVMTQSPDSLAVSLGERATINCKSSQSVTYNYKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGT
DFTLTISSLQAEDVAVYYCQQYYRTPPTFGGGTKLDIKGSVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
(SEQ ID NO: 95)



CDR-H1
CDR-H2
CDR-H3
VH15 EVQLLESGGG LVKPGQSLKL SCAASGFTFT SYGMHWVRQP PGKGLEWVAV ISYDGSYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG AGTTLTVSS
VH16 EVQLLESGGG LVKPGQSLKL SCAASGFTFS SYGMHWVRQP PGKGLEWVAV VSYDGSNKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDI KLRSLLYFEW LSSGLLDYWG QGAMVTVSS
VH17 EVQLLESGGG LVKPGQSLKL SCAASGFTFI SYGMHWVRQP PGKGLEWVAV VSYDGNYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG AGTTLTVSS
VH18 EVQLLESGGG LVKPGQSLKL SCAASGFTFT SYGMHWVRQP PGKGLEWVAV LSYDGNYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG AGTTLTVSS
VH19 EVQLLESGGG LVKPGQSLKL SCAASGFTFT TYAMHWVRQP PGKGLEWVAV LSYDGHYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG AGTTLTVSS
VH21 EVQLLESGGG LVKPGQSLKL SCAASGFTFS SYGMHWVRQP PGKGLEWVAV VSYDGNNKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS KLRSLLYFEW LSSGLLDYWG QGAMVTVSS
VH22 EVQLLESGGG LVKPGQSLKL SCAASGFTFT TYAMHWVRQP PGKGLEWVAV VSYDGNNKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS KLRSLLYFEW LSSGLLDYWG QGAMVTVSS
VH20 EVQLLESGGG LVKPGQSLKL SCAASGFTFT TYAMHWVRQP PGKGLEWVAV VSFDGNNRYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS QLRSLLYFEW LSSGVLDYWG QGAMVTVSS
VH23 EVQLLESGGG LVKPGQSLKL SCAASGFIFI SYGMHWVRQP PGKGLEWVAV VSYDGNYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS KLRSLLYFEW LSQGYFNPWG AGTTLTVSS
VH24 EVQLLESGGG LVKPGQSLKL SCAASGFTFI SYAMHWVRQP PGKGLEWVAV VSYDGHYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG QGTTLTVSS
VH25 QVQLLETGGG LVKPGQSLKL SCAASGFTFT SYAMHWVRQP PGKGLEWVAV VSYDGHYKYY ADSVQGRFTI SRDNSLRAED TAVYYCAKDS RLRSLLYFEW LSQGYFNPWG QGTTLTVSS
VH26 EVQLLESGGG LVKPGQSLKL SCAASGFTFT SYAMHWVRQP PGKGLEWVAV VSYDGNYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS QLRTLLYFEW LSQGYFNPWG QGTTLTVSS
VH27 EVQLLESGGG LVKPGQSLKL SCAASGFTFI SYAMHWVRQP PGKGLEWVAV VSYDGNYKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS RLRTLLYFEW LSQGYFDPWG QGTTLTVSS
VH161 EVQLLESGGG LVKPGQSLKL SCAASGFTFS SYGMHWVRQP PGKGLEWVAV VSYDGSNKYY ADSVQGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDS KLRSLLYFEW LSSGLLDYWG QGAMVTVSS

FIG. 2

FIG. 3



CDR-L1
CDR-L2
CDR-L3
10 20 30 40 50 60 70 80 90 100 110
VL28 EIVMTQSPDS LAVSLGERAT INCKSSQSVT YNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQYYRTPP TFGGGTKLDI K
VL29 EIVMTQSPDS LAVSLGERAT INCKSSQSVT FSYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQYYRTPP TFGGGTKLDI K
VL30 EIVMTQSPDS LAVSLGERAT INCKSSQSVT FDYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQYYRTPP TFGGGTKLDI K
VL35 EIVMTQSPDS LAVSLGERAT INCKSSQSVT WSYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQYYRTPP TFGGGTKLDI K
VL31 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGGGTKLDI K
VL32 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGGGTKLDI K
VL33 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYFASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGGGTKLDI K
VL34 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYFASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGGGTKLDI K
VL36 EIVMSQSPDI LAVTLGERAS INCKSSQTVT FNYKNYLAWY QQKPGQPPKV LIYWASARET GVPERFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLEI K
VL45 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL46 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLGWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL37 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGSGTKLDI K
VL38 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL39 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL40 EIVMTQSPDS LAVSLGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGNGTKLDI K
VL41 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGSGTKLDI K
VL42 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL43 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL44 EIVMTQSPDS LAVSLGERAT INCKSSQTLS FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGNGTKLDI K
VL47 DIVMTQSPDI LAVTLGERAT IQCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIT SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL48 DIVMTQSPDI VAVTVGERAT INCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGIDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL49 DIVMTQSPDI VAVTLGERAI IDCKSSQTVI FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL50 DIVMTQSPDT LAVTVGERAT IRCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQHYRTPP SFGQGTKLDI K
VL51 DIVMTQSPDI LAVSRGERAT IDCKSSQTVT FNYKNYLAWY QQKPGQPPKL LIYWASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDEAVY YCQQHYRTPP SFGQGTKLDI K
VL52 DIQMTQSPSS LSASVGDRVI ITCRSSQSII FDYKNYLAWY QQRPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL53 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSTLES GVPSRFSGSG SGIDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL54 DIQMTQSPSS LSASVGDRVI ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSHLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRIPP SFGQGTKVEI K
VL55 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSKLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL56 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNTLAWY QQKPGKAPKL LIYWGSDLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL57 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDVATY YCQQHYRTPP SFGQGTKVEI K
VL58 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDKATY YCQQHYRTPP SFGQGTKVEI K
VL59 DIQMTQSPSS LSASVGDRVI ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGIDFTLTIS SLQPEDDATY YCQQHYRTPP SFGQGTKVEI K
VL60 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQYYRTPP SFGQGTKVEI K
VL61 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQRPGKAPKL LIYWGSTRES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL153 DIQMTQSPSS LSASVGDRVI ITCRSSQSII FQYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL154 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FRYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL155 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FEYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL156 DIQMTQSPSS LSASVGDRVI ITCRSSQSII FDYKNYLAWY QQKPGKAPKL LIYWGSTRES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K
VL62 DIQMTQSPSS LSASVGDRVT ITCRSSQSII FNYKNYLAWY QQKPGKAPKL LIYWGSYLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQHYRTPP SFGQGTKVEI K

FIG. 4



25000000
20000000
15000000
10000000
5000000
0
X31 Titer: PFU/ml
0 ug/ml
A18
10 ug/ml
A18
50 ug/ml
AB1
10 ug/ml
AB1
50 ug/ml

FIG. 5



3.000
2.500
2.000
1.500
1.000
0.500
0.000
O.D. A450
H3 Wyoming/03
H3 Brisbane/07
0.000
5.000
10.000
15.000
20.000
25.000
Protein Concentration (ug/ml)

FIG. 6



3.000
2.500
2.000
1.500
1.000
0.500
0.000
O.D. A450
0.000
5.000
10.000
15.000
20.000
25.000
Protein Concentration (ug/mL)
H3 Bris07 HA
H3N2 Bris07 virus
BSA

FIG. 7A



Weight Change in H1N1 - Challenged Mice
5.00
0.00
-5.00
-10.00
-15.00
-20.00
-25.00
-30.00
Weight change (%)
0
7
14
Days post infection
PBS
A18 therapy 48 h pi

FIG. 7B



Weight Change in H3N2 - Challenged Mice
5.00
0.00
-5.00
-10.00
-15.00
-20.00
-25.00
Weight change (%)
0
7
14
Days post infection
PBS
A18 therapy 48 h pi
A18 prophylaxis

FIG. 8A



Percent survival
100
80
60
40
20
0
0
7
14
Time (days)
Untreated
Ab 028 at 10 mg/kg
Ab 031 at 10 mg/kg
Ab 032 at 10 mg/kg

FIG. 8B



Percent survival
100
80
60
40
20
0
0
7
14
Time (days)
Untreated
Ab 028 at 10 mg/kg
Ab 031 at 10 mg/kg
Ab 032 at 10 mg/kg

FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 11



% Viral Titer
70
60
50
40
30
20
10
0
R1: AB1
R1: C179
R2: AB1
R2: C179
R3: AB1
R3: C179
R4: AB1
R4: C179
R5: AB1
R3: C179

FIG. 12

```
F16 VH      QVQLVQSGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVISYDGNYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSQLRSLLYFEWLSQGYFDYWGQGTLVTVSS
F16/3H0 VH QVQLVQSGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGNYKYYADSVKGRFTISRDNSKNTLYLQMNSLRTEDTALYYCAKDSQLRSLLYFDWLSQGYFDHWGQGTLVTVSS
F16 VH v1    QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSQLRSLLYFDWLSQGYFDYWGQGTLVTVSS
F16 VH v3    QVQLVESGGGVVQPGRSLRLSCAASGFTFSTYAMHWVRQAPGKGLEWVAVISYDANYKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDSQLRSLLYFEWLSQGYFDYWGQGTLVTVSS
F16/3H0 VK QVQLVQSGGGVVQPGRSLRLSCAASGFTFSTYGMHWVRQAPGKGLEWVAVISYDGNYKYYADSVKGRFTISRDNSKNTLYLQMNSLRSLLYFDWLSQGYFDHWGQGTLVTVSS
F16VK      DIQMTSQPDSLAVSLGARATINCKSSQSVTFNYKNYLAWYQQKPGQPPKVLIYWASARESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYRTPPTFGQGTKVEIK
```

FIG. 13




FIG. 14




FIG. 15



pH 5.0
pH 7.0
Syncitia #/field (20X lense)
30
25
20
15
10
5
0
Pre
Post
Pre
Post
Ab 032
(µg/ml)
100
10
0

FIG. 16



Vehicle
Ribavirin
Azithromycin
Ab 032 Prophylaxis
Ab 032 Therapy
Ab 028 Therapy
Days

FIG. 17

Additional Light Chain Variable Regions

VL165
DIQMTQSPSSLSASVGDRVTITCRSSQSITWNYKNYLAWYQQKPGKAPKLLIYWGSYLESGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQHYRTPPSFGQGTKVEIK

VL166
DIQMTQSPSSLSASVGDRVTITCRSSQSITWDYKNYLAWYQQKPGKAPKLLIYWGSYLESGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQHYRTPPSFGQGTKVEIK

VL167
DIQMTQSPSSLSASVGDRVTITCRSSQSITWQYKNYLAWYQQKPGKAPKLLIYWGSYLESGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQHYRTPPSFGQGTKVEIK

VL168
DIQMTQSPSSLSASVGDRVTITCRSSQSITWRYKNYLAWYQQKPGKAPKLLIYWGSYLESGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQHYRTPPSFGQGTKVEIK

VL169
DIQMTQSPSSLSASVGDRVTITCRSSQSITWEYKNYLAWYQQKPGKAPKLLIYWGSYLESGVPSRFSGSGSGTD
FTLTISSLQPEDFATYYCQQHYRTPPSFGQGTKVEIK

Additional Heavy Chain Variable Regions

VH164
QVQLLETGGGLVKPGQSLKLSCAASGFTFTSYAMHWVRQPPGKGLEWVAVVSYDGNYKYYADSVQGRFTISR
DNSKNTLYLQMNSLRAEDTAVYYCAKDSRLRSLLYFEWLSQGYFNPWGQGTTVTVSS

VH162
EVQLLESGGGLVKPGQSLKLSCAASGFSFSTYAMHWVRQPPGKGLEWVAVVSYDGNYKYYADTVQGRFTISRD
NSKNTLYLQMNSLRAEDTAVYYCAKDSRLRSLLYFEWLSQGYFNPWGQGTTLTVSS

VH163
EVQLLESGGGLRKPGQSLKLSCAASGFSFSTYAMHWVRQPPGKGLEWVAVVSYDGNYKYYADSVQGRFTISR
DNSKNTLYLQMNSLRAEDTAVYYCAKDSRLRSLLYFEWLSQGYFNPWGQGTTLTVSS

FIG. 18



800
700
600
500
400
300
200
100
0
No. of Syncitias
pH 5.0
pH 7.0
0.00
0.20
0.78
3.13
12.50
50.00
Concentration of Ab 044 (µg/ml)

FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B




FIG. 21A

Treatment Group	Lung Viral Load H1N1 (PFU/ml)
Untreated	6.03
Ab 044 Prophylaxis 10 mg/Kg	4.45
Ab 044 Prophylaxis 2.5 mg/Kg	4.08
Ab 044 Prophylaxis 0.6 mg/Kg	5.38
Ab 044 Therapy 10 mg/Kg (48hpi)	5.34
Ab 044 Therapy 2.5 mg/Kg (48 hpi)	5.49
Ab 044 Therapy 0.6 mg/Kg (48hpi)	5.74
Ab 044 Therapy 20 mg/Kg (72hpi)	5.29

FIG. 21B

Treatment Group	Lung Viral Load H3N2 (PFU/ml)
Untreated	6.48
Ab 044 Prophylaxis 10 mg/Kg	5.42
Ab 044 Therapy 10 mg/Kg (48hpi)	5.46
Ab 044 Therapy 2.5 mg/Kg (48 hpi)	5.99
Ab 044 Therapy 0.6 mg/Kg (48hpi)	6.44
Ab 044 Therapy 20 mg/Kg (72hpi)	5.64

FIG. 22A




FIG. 22B




FIG. 23A




FIG. 23B




FIG. 24




Weight (g)
22
20
18
16
14
12
-1
2
5
8
11
14
17
20
Day Post-Virus Exposure
PSS (qd X 1, +48h)
Ab 044 (20 mg/kg/d, qd X 1, -24)
Ab 044 (10 mg/kg/d, qd X 1, -24)
Ab 044 (5 mg/kg/d, qd X 1, -24)
Ab 044 (20 mg/kg/d, qd X 1, +24)
Ab 044 (20 mg/kg/d, qd X 1, +48)
Oseltamivir (30 mg/kg/d, bid X 5, 0h)

FIG. 25



PSS (qd X 1, +48h)
Ab 044 (20 mg/kg/d, qd X 1, -24) **** P<0.0001 vs. PSS
Ab 044 (10 mg/kg/d, qd X 1, -24) **** P<0.0001 vs. PSS
Ab 044 (5 mg/kg/d, qd X 1, -24) **** P<0.0001 vs. PSS
Ab 044 (20 mg/kg/d, qd X 1, +24) **** P<0.0001 vs. PSS
Ab 044 (20 mg/kg/d, qd X 1, +48) **** P<0.0001 vs. PSS
Oseltamivir (30 mg/kg/d, bid X 5, 0h) ** P = 0.0055 vs. PSS

FIG. 26




FIG. 27

